FDA Inspection 1231825 — Erode Cancer Centre
The FDA completed an inspection of Erode Cancer Centre on November 21, 2023 in Thindal. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- November 21, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Thindal (India)
Additional Details
Clinical BA/BE